ea0098c7 | Clinical – Chemo/SSA/Biologics | NANETS2023
Owen Dwight H.
, Sukrithan Vineeth
, Benner Brooke
, Wei Lai
, Goyal Ashima
, Zhou Ye
, Pilcher Carly
, Curtis Nancy
, Jukich Megan
, Schwarz Emily
, Savardekar Himanshu
, Norman Ruthann
, Ferguson Sarah
, Kleiber Barbara
, Wesolowski Robert
, Carson William E.
, Gregory A. Otterson III,
, Verschraegen Claire F.
, Shah Manisha H.
, Konda Bhavana
Background: Treatment options are limited in patients with metastatic neuroendocrine neoplasms (NEN). Combination temozolomide and nivolumab showed encouraging objective response rates of 35.7% in advanced NEN regardless of site of origin, with response rates of 64% in lung NEN and 67% in pancreatic NEN (NCT03728361). We present updated survival data on follow-up from a phase II trial of combination nivolumab and temozolomide in patients with advanced NEN.<p class="abstext...